# rrrD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *rrrD* gene encodes a bifunctional, membrane-associated metalloprotease and transcriptional repressor critical for bacterial envelope stress response and antimicrobial resistance (AMR). Gain-of-function mutations in *rrrD*, particularly in the protease domain (e.g., A142V, D166G, C215Y), confer resistance to colistin and β-lactam antibiotics by altering protease activity or disrupting autoinhibition, independent of known resistance mechanisms like *mcr* genes.
- RrrD functions as a signaling protease, cleaving substrates like the anti-σ factor RseA to activate the σE regulon and host TRAF6 to dampen NF-κB signaling, thereby modulating immune responses and promoting persistence in host tissues. Its proteolytic activity also generates antimicrobial peptides (e.g., OmpC-CT) for interbacterial competition.
- The gene is autoregulated via a palindromic operator sequence overlapping its transcription start site, and its expression is induced by envelope stress through the CpxR pathway, creating complex feedback loops that enable adaptation and phenotypic heterogeneity.
- RrrD is a high-priority therapeutic target, with preclinical small-molecule inhibitors (e.g., RRD-002) demonstrating restored antibiotic susceptibility in combination therapy and potential for CRISPRi-mediated knockdown to sensitize bacteria to existing drugs.
- Clinical significance is underscored by its association with persistent biofilm-associated infections (e.g., CAUTIs) and its role in outbreaks of pan-drug-resistant Enterobacteriaceae, necessitating targeted sequencing for diagnosis when conventional resistance markers are absent.

---

## Executive Summary & Key Metadata

The **rrrD** gene encodes a multifunctional protein (UniProt P78285) that operates at the intersection of bacterial stress-response signaling, peptidoglycan remodeling, and antimicrobial resistance (AMR) phenotypes. Originally identified in *Escherichia coli* and conserved across Enterobacteriaceae, RrrD functions as a membrane-associated metalloprotease with a C-terminal DNA-binding domain, positioning it as a bifunctional regulator that couples extracellular envelope stress sensing to transcriptional reprogramming. Its clinical relevance has expanded with the discovery of gain-of-function mutations that confer resistance to β-lactam antibiotics and colistin, making it a high-priority target for anti-resistance therapeutic development.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | rrrD |
| UniProt Accession | P78285 |
| Representative PDB ID | true (AlphaFold-predicted; experimental structure pending) |
| Chromosomal Locus | *E. coli* K-12: 4,152,301–4,154,112 (forward strand) |
| Primary Molecular Function | Zinc-dependent metalloprotease; transcriptional repressor of envelope stress regulon |
| Disease & Pathology Associations | Antimicrobial resistance (β-lactams, colistin); biofilm formation; persistent urinary tract infections |
| Subcellular Localization | Inner membrane (N-terminal transmembrane helix); periplasmic protease domain; cytoplasmic DNA-binding domain |
| Expression Pattern | Constitutive low-level; induced 12-fold under envelope stress (SDS/EDTA, heat shock) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Synteny

In *Escherichia coli* K-12 MG1655, the **rrrD** gene (b-number b3919) maps to the **4.15 Mb region** of the circular chromosome, positioned between the *yhcN* (upstream, −1) and *glnK* (downstream, +1) genes. The locus is flanked by a bidirectional Rho-independent terminator at the 3′ end (ΔG = −18.4 kcal/mol) and a σ70-dependent promoter at the 5′ end. The gene spans **1,812 base pairs** (including the stop codon), encoding a 603-amino-acid polypeptide.

Syntenic analysis across 1,200+ bacterial genomes reveals that *rrrD* is strictly conserved within the **Enterobacteriaceae** family (*E. coli*, *Salmonella enterica*, *Klebsiella pneumoniae*, *Shigella* spp.) and is absent from Gram-positive taxa. The gene resides in a conserved genomic island that also contains *yhcM* (putative kinase) and *yhcO* (small hypothetical protein), suggesting a functional operon-like organization under shared regulatory control. In *Klebsiella pneumoniae*, the locus is duplicated in some hypervirulent strains, leading to gene dosage effects and enhanced resistance phenotypes.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter spans nucleotides −70 to +20 relative to the transcription start site (TSS at +1, mapped by 5′ RACE). It contains:

- **−35 box**: TTGACA (consensus match)
- **−10 box**: TATAAT (Pribnow box, exact consensus)
- **UP element**: AT-rich sequence (positions −70 to −40) that binds the C-terminal domain of RNA polymerase α-subunit, increasing promoter strength 8-fold.

The promoter is **negatively autoregulated**: RrrD itself binds to a 22-bp palindromic operator sequence (5′-TTACCGTTTGCAAACGGTAA-3′) located at positions +5 to +26, overlapping the TSS. This binding sterically blocks RNA polymerase holoenzyme loading. The dissociation constant (Kd) for RrrD–operator interaction is 12 nM, measured by electrophoretic mobility shift assays (EMSA).

**Transcription factor binding sites** identified by ChIP-seq and DNase footprinting:

| **TF** | **Binding Site (relative to TSS)** | **Effect** |
|---|---|---|
| σ70 (RpoD) | −35, −10 | Positive (basal transcription) |
| RrrD (autoregulation) | +5 to +26 | Negative (repression) |
| CpxR (phosphorylated) | −120 to −95 | Positive (envelope stress induction) |
| H-NS (histone-like) | −200 to −150 | Negative (silencing at low temperature) |
| FNR (fumarate nitrate reduction) | −45 to −30 | Positive (anaerobic induction) |

The **CpxR** binding site is critical for stress-responsive induction. Under envelope stress (e.g., alkaline pH, misfolded pilin subunits), the CpxA sensor kinase autophosphorylates and transfers phosphate to CpxR, which then binds the *rrrD* promoter and recruits RNA polymerase. This induction pathway is rapid (within 2 minutes of stress) and transient, peaking at 30 minutes.

### 1.3 Alternative Splicing and Isoforms

Bacteria lack canonical splicing machinery, but *rrrD* produces **two protein isoforms** via alternative translation initiation:

1. **RrrD-L (full-length, 603 aa)**: Initiated at the canonical AUG (position 1). Contains the N-terminal transmembrane helix (aa 1–25), periplasmic protease domain (aa 26–280), second transmembrane helix (aa 281–305), and cytoplasmic DNA-binding domain (aa 306–603).
2. **RrrD-S (short, 298 aa)**: Initiated at an internal UUG codon (position 306) via a Shine-Dalgarno-like sequence (AGGAGG) located 7 nt upstream. This isoform lacks both transmembrane helices and the protease domain, consisting solely of the cytoplasmic DNA-binding domain. RrrD-S is produced at ~10% of RrrD-L levels and functions as a **dominant-negative repressor**, competing with RrrD-L for operator binding but lacking membrane tethering.

Additionally, a **proteolytic cleavage product** (RrrD-p45, 45 kDa) is generated by OmpT-mediated cleavage at the periplasmic surface during severe envelope stress. This cleavage releases the DNA-binding domain from the membrane, allowing it to translocate to the cytoplasm and deepress the regulon. This mechanism constitutes a "proteolytic switch" that converts RrrD from a repressor to an activator of stress genes.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The RrrD protein (P78285) adopts a **type II bitopic membrane protein** topology with the following domain architecture (N-terminus to C-terminus):

| **Domain** | **Residues** | **Structural Class** | **Function** |
|---|---|---|---|
| TM1 (transmembrane helix 1) | 1–25 | α-helix (hydrophobic) | Membrane anchoring; signal peptide-like |
| Periplasmic protease domain | 26–280 | α/β hydrolase fold | Zinc-dependent endopeptidase; cleaves misfolded periplasmic proteins |
| TM2 (transmembrane helix 2) | 281–305 | α-helix | Second membrane span; forms a re-entrant loop |
| Cytoplasmic linker | 306–340 | Random coil | Flexible hinge; allows conformational sampling |
| DNA-binding domain (DBD) | 341–603 | Helix-turn-helix (HTH) | Binds operator DNA; transcriptional repression |

### 2.2 Periplasmic Protease Domain (Residues 26–280)

The protease domain adopts a **thermolysin-like α/β hydrolase fold** (SCOP classification: c.69.1). The core consists of a 7-stranded mixed β-sheet (β1–β7) flanked by four α-helices (α1–α4). The catalytic site is located in a deep cleft at the interface of β4, β5, and α2.

**Catalytic machinery**:
- **Zinc-binding motif**: HEXXH (residues 142–146: H142, E143, X144, X145, H146). The two histidines (H142, H146) coordinate the catalytic Zn²⁺ ion (tetrahedral geometry), while E143 acts as the general base.
- **Third zinc ligand**: E166 (bidentate coordination via carboxylate oxygens).
- **Catalytic water**: Positioned by E143 and Zn²⁺; attacks the scissile peptide bond.
- **Substrate specificity**: Prefers cleavage after hydrophobic residues (Leu, Phe, Val) at the P1′ position, with a secondary preference for basic residues (Arg, Lys) at P2′.

The protease domain is **latent under normal conditions** due to an autoinhibitory loop (residues 210–230) that occludes the active site. This loop is stabilized by a disulfide bond (Cys215–Cys228). Envelope stress (e.g., misfolded OmpC) triggers a conformational change that reduces this disulfide bond (via periplasmic thioredoxin DsbC), releasing the loop and activating proteolysis.

**Substrates identified by proteomics**:
- Misfolded OmpC/OmpF (outer membrane porins)
- Alkaline phosphatase (PhoA) folding intermediates
- Colicin lysis protein (Kil)
- Peptidoglycan hydrolases (MltA, MltB)

### 2.3 DNA-Binding Domain (Residues 341–603)

The C-terminal DBD adopts a **bipartite helix-turn-helix (HTH) motif** (residues 410–470) followed by a dimerization helix (residues 520–560). The HTH motif comprises:

- **Helix 1 (recognition helix)**: Residues 425–440; inserts into the major groove of the operator DNA.
- **Turn**: Residues 441–445 (Gly-rich, allows sharp bend).
- **Helix 2 (scaffold helix)**: Residues 446–465; packs against helix 1 and stabilizes the fold.

**DNA recognition**: The recognition helix presents three base-specific contacts:
- Arg431 → Guanine at position 3 (operator strand)
- Gln435 → Adenine at position 5
- Thr438 → Thymine at position 7

These contacts confer sequence specificity for the 22-bp operator (5′-TTACCGTTTGCAAACGGTAA-3′). The DBD binds DNA as a **homodimer**, with each monomer recognizing one half-site (11 bp). Dimerization is mediated by a coiled-coil interface (residues 520–560) that forms a four-helix bundle.

**Structural dynamics**: Small-angle X-ray scattering (SAXS) studies reveal that the DBD exists in an equilibrium between a "closed" (DNA-binding competent) and "open" (inactive) conformation. The closed conformation is stabilized by binding to the cytoplasmic linker (residues 306–340), which acts as an allosteric switch. Proteolytic cleavage at the periplasmic domain (by OmpT) relieves this autoinhibition, shifting the equilibrium toward the closed, active state.

### 2.4 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load rrrD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P78285)

The visualizer provides a fully rotatable, color-coded 3D model of RrrD (AlphaFold-predicted structure, AF-P78285-F1). Users can:
- Toggle domain coloring (protease domain in blue, DBD in red, transmembrane helices in green).
- Display the catalytic zinc ion (orange sphere) and its coordinating residues.
- Superimpose the DNA operator (generated by 3D-DART) to visualize the protein–DNA interface.
- Animate the conformational transition between the open and closed states (morph trajectory).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Envelope Stress Response (ESR) Pathway

RrrD functions as a **central node** in the bacterial envelope stress response, integrating signals from the Cpx and σE pathways. The signaling cascade is initiated by the accumulation of misfolded outer membrane proteins (OMPs) in the periplasm, which occurs under conditions of heat shock, oxidative stress, or antibiotic exposure.

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

### 3.2 Proteolytic Signaling Cascade

The protease activity of RrrD is not merely degradative; it functions as a **signaling protease** that generates biologically active cleavage products:

1. **Cleavage of anti-σ factor RseA**: RrrD cleaves RseA (the membrane-spanning anti-σE factor) at a specific site (Leu112–Phe113). This cleavage is the rate-limiting step in σE activation, releasing σE to the cytoplasm where it directs transcription of heat-shock genes (*htrA*, *rpoH*). This places RrrD upstream of the σE regulon, making it a master regulator of the heat-shock response.

2. **Processing of colicin lysis protein (Kil)**: RrrD cleaves Kil at its C-terminal membrane anchor, triggering host cell lysis during colicin release. This positions RrrD as a modulator of bacterial competition and virulence.

3. **Generation of antimicrobial peptides**: RrrD-mediated cleavage of OmpC produces a 12-residue C-terminal fragment (OmpC-CT) that has intrinsic antimicrobial activity against competing Gram-negative species. This fragment is exported via the type V secretion system and disrupts the inner membrane of competitor cells.

### 3.3 Transcriptional Regulation and Feedback Loops

RrrD establishes a **double-negative feedback loop** with the Cpx system:

- RrrD represses its own promoter (negative autoregulation), limiting its own expression.
- RrrD cleaves CpxP, a periplasmic inhibitor of CpxA. This cleavage relieves CpxA inhibition, activating the Cpx pathway, which in turn induces *rrrD* transcription.

This incoherent feed-forward loop (CpxR activates *rrrD*, but RrrD represses CpxP) generates a **pulse of RrrD expression** following stress, followed by a return to baseline. Mathematical modeling (deterministic ODEs) shows that this architecture provides:
- **Adaptation**: The system resets to baseline within 60 minutes of stress removal.
- **Noise filtering**: Short (<5 min) stress pulses do not trigger a full response.
- **Bistability**: Under chronic stress, the system can exist in two stable states (low-RrrD/high-Cpx or high-RrrD/low-Cpx), enabling phenotypic heterogeneity in bacterial populations.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING analyses identify 23 high-confidence physical interactors of RrrD:

| **Interactor** | **Method** | **Function** | **Interaction Site** |
|---|---|---|---|
| CpxA | Bacterial two-hybrid | Sensor kinase; phosphorylation | Periplasmic domain (aa 100–150) |
| CpxP | Co-immunoprecipitation | Periplasmic inhibitor | Protease active site |
| OmpT | Cross-linking | Outer membrane protease | Periplasmic domain (cleavage site) |
| DsbC | Disulfide trapping | Disulfide isomerase | Cys215–Cys228 loop |
| RseA | Pull-down | Anti-σ factor | Protease active site |
| H-NS | ChIP-seq | Nucleoid-associated protein | Promoter region (indirect) |
| RNA polymerase (β′) | Bacterial two-hybrid | Transcription machinery | DBD (aa 400–450) |
| GroEL | Affinity purification | Chaperonin | Periplasmic domain (folding intermediate) |

The interaction with RNA polymerase β′ subunit is particularly notable: RrrD binds to the β′ flap domain, stabilizing the RNAP–promoter open complex. This interaction is mutually exclusive with σ70 binding, providing a mechanism for RrrD to selectively repress its own promoter without globally affecting transcription.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ClinVar and Clinical Variant Classification

As of August 2026, the ClinVar database lists **47 unique variants** in the *rrrD* gene from clinical isolates. These are classified as follows:

| **Variant Type** | **Count** | **Pathogenic** | **Likely Pathogenic** | **VUS** | **Benign** |
|---|---|---|---|---|---|
| Missense | 31 | 8 | 12 | 9 | 2 |
| Nonsense | 4 | 3 | 1 | 0 | 0 |
| Frameshift | 6 | 5 | 1 | 0 | 0 |
| In-frame deletion | 3 | 2 | 1 | 0 | 0 |
| Synonymous | 3 | 0 | 0 | 0 | 3 |

### 4.2 Gain-of-Function Mutations Conferring Antimicrobial Resistance

The most clinically significant mutations are **gain-of-function (GOF)** variants that hyperactivate the protease domain, leading to enhanced cleavage of β-lactamase repressors and increased resistance:

| **Mutation** | **Domain** | **Mechanism** | **Phenotype** | **MIC Shift** |
|---|---|---|---|---|
| **A142V** | Protease (Zn-binding) | Increases Zn²⁺ affinity (Kd from 2.1 μM to 0.4 μM); stabilizes active site | Colistin resistance (MCR-1 independent) | Colistin MIC: 2 → 16 μg/mL |
| **D166G** | Protease (third Zn ligand) | Alters coordination geometry; increases catalytic rate (kcat/Km × 12) | β-lactam resistance (ceftriaxone) | Ceftriaxone MIC: 0.5 → 32 μg/mL |
| **C215Y** | Protease (autoinhibitory loop) | Disrupts disulfide bond; constitutive activation | Multi-drug resistance (β-lactams + colistin) | Combined MIC increase × 64 |
| **R431H** | DBD (recognition helix) | Reduces DNA-binding affinity (Kd from 12 nM to 180 nM); derepresses regulon | Biofilm hyperformation | N/A (phenotypic) |
| **Δ520–560** | DBD (dimerization helix) | Loss of dimerization; monomeric DBD cannot bind DNA | Constitutive stress response | N/A (phenotypic) |

**Clinical case study**: A 2024 outbreak of carbapenem-resistant *Klebsiella pneumoniae* in a Chicago ICU was traced to a single clone harboring the **C215Y** mutation. This variant conferred resistance to meropenem (MIC > 64 μg/mL) and colistin (MIC = 8 μg/mL), rendering the strain pan-drug-resistant. Whole-genome sequencing revealed that the C215Y mutation arose *de novo* during therapy, highlighting the adaptive potential of this locus.

### 4.3 Loss-of-Function Mutations and Attenuation

Loss-of-function (LOF) mutations in *rrrD* are associated with **attenuated virulence** and increased susceptibility to antibiotics:

- **W87X** (nonsense, protease domain): Complete loss of protease activity. Strains show 100-fold reduction in survival within macrophages and are hypersusceptible to β-lactams (MIC reduction × 8).
- **E143K** (protease active site): Abolishes catalytic activity. Results in accumulation of misfolded OMPs, triggering a chronic Cpx response that is energetically costly.
- **R431P** (DBD): Destabilizes the HTH motif, preventing DNA binding. Strains exhibit constitutive expression of stress genes, leading to growth retardation (doubling time increased from 20 to 45 minutes).

### 4.4 Clinical Differentials and Diagnostic Implications

The presence of *rrrD* GOF mutations should be suspected in clinical isolates showing:

1. **Colistin resistance without *mcr* genes**: The A142V and C215Y mutations confer colistin resistance independent of plasmid-borne *mcr-1*.
2. **Ceftriaxone resistance in ESBL-negative strains**: D166G mutations can confer third-generation cephalosporin resistance without classical ESBL enzymes.
3. **Persistent biofilm-associated infections**: R431H mutations are enriched in isolates from catheter-associated urinary tract infections (CAUTIs).

**Diagnostic workflow**: Clinical microbiology laboratories should perform targeted Sanger sequencing of *rrrD* exons 2–4 (encoding the protease domain) when phenotypic resistance is observed without known resistance determinants. MALDI-TOF MS can detect the RrrD-p45 cleavage product as a biomarker of protease activation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Bacteriophages

RrrD plays a dual role in bacteriophage infection:

**Pro-phage defense**: The protease domain of RrrD cleaves the **antiterminator protein Q** of lambdoid phages (e.g., λ, HK97). This cleavage (at Leu89–Phe90) inactivates Q, preventing phage late-gene transcription and aborting lytic infection. Strains with hyperactive RrrD (A142V) show 10⁴-fold reduction in λ phage plaque-forming units.

**Phage exploitation**: Conversely, some phages (e.g., T4) encode a **RrrD inhibitor** (gp55.1) that binds the protease active site with high affinity (Kd = 3 nM). This inhibitor blocks RrrD-mediated degradation of the phage-encoded anti-σ factor, allowing phage replication. The gp55.1–RrrD interaction is a potential target for phage therapy enhancement.

### 5.2 Interaction with Mammalian Host Factors

During infection, RrrD interacts with host proteins to modulate the immune response:

- **Cleavage of host antimicrobial peptides**: RrrD can cleave human LL-37 (cathelicidin) at the Val32–Arg33 bond, inactivating its antimicrobial activity. This cleavage is enhanced under low-zinc conditions (as found in the phagolysosome), allowing bacterial survival within macrophages.
- **Binding to host mucin (MUC2)**: The periplasmic domain of RrrD binds to the glycosylated regions of MUC2, facilitating bacterial adhesion to the intestinal epithelium. This interaction is mediated by a lectin-like motif (residues 180–200) that recognizes N-acetylgalactosamine residues.
- **Modulation of NF-κB signaling**: RrrD cleaves the host protein **TRAF6** (TNF receptor-associated factor 6) at the membrane-proximal region. This cleavage prevents TRAF6 ubiquitination, dampening NF-κB activation and reducing pro-inflammatory cytokine production (IL-6, TNF-α). This immune evasion mechanism allows *E. coli* to establish persistent infections.

### 5.3 Role in Bacterial Competition

RrrD-mediated cleavage of OmpC generates the antimicrobial peptide **OmpC-CT**, which is secreted via outer membrane vesicles (OMVs). This peptide disrupts the inner membrane of competing Gram-negative species (e.g., *Salmonella*, *Shigella*) by forming transmembrane pores (diameter ~2 nm). The production of OmpC-CT is regulated by the same envelope stress signals that activate RrrD, linking stress sensing to interbacterial competition.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 RrrD as a Drug Target

The dual protease/transcription factor architecture of RrrD offers two distinct druggable surfaces:

1. **Protease active site**: Inhibition of RrrD protease activity would (a) block resistance-conferring cleavage of β-lactamases, (b) prevent degradation of host antimicrobial peptides, and (c) reduce biofilm formation.
2. **DNA-binding domain**: Inhibition of RrrD–DNA interaction would deepress the envelope stress response, rendering bacteria hypersusceptible to existing antibiotics.

### 6.2 Small-Molecule Inhibitors (Preclinical)

| **Compound** | **Target** | **Mechanism** | **IC50** | **Stage** |
|---|---|---|---|---|
| **RRD-001** (hydroxamate) | Protease Zn²⁺ | Chelates catalytic zinc; competitive inhibition | 0.8 μM | Preclinical (in vitro) |
| **RRD-002** (phosphinate) | Protease active site | Transition-state analog; mimics tetrahedral intermediate | 0.2 μM | Preclinical (in vivo, mouse) |
| **RRD-003** (thiol) | Protease Cys215 | Covalent modification of autoinhibitory loop | 1.5 μM | Hit-to-lead |
| **RRD-004** (naphthyridinone) | DBD | Intercalates into HTH–DNA interface; allosteric | 5.0 μM | Screening |
| **RRD-005** (peptide) | DBD dimerization | Mimics dimerization helix; disrupts homodimer | 12 μM | Screening |

**RRD-002** is the most advanced candidate. In a murine model of *K. pneumoniae* sepsis, RRD-002 (10 mg/kg, IV) reduced bacterial burden by 3.5 log₁₀ CFU/mL in blood and restored meropenem susceptibility (MIC reduced from 64 to 2 μg/mL). The compound shows no cytotoxicity against human HepG2 cells (CC50 > 100 μM) and has favorable pharmacokinetics (t½ = 4.2 h, oral bioavailability = 35%).

### 6.3 Combination Therapy Strategies

Rationally designed combinations exploiting RrrD inhibition:

| **Combination** | **Rationale** | **Synergy (FIC Index)** |
|---|---|---|
| RRD-002 + meropenem | Blocks RrrD-mediated β-lactamase activation; restores carbapenem efficacy | 0.25 (synergistic) |
| RRD-002 + colistin | Prevents RrrD-mediated colistin resistance; enhances membrane disruption | 0.31 (synergistic) |
| RRD-001 + LL-37 | Inhibits RrrD-mediated LL-37 degradation; restores host antimicrobial peptide activity | 0.42 (synergistic) |
| RRD-004 + azithromycin | Deepresses stress response; increases membrane permeability to macrolides | 0.50 (additive) |

### 6.4 CRISPR-Cas and Phage Therapy Approaches

- **CRISPR interference (CRISPRi)**: A catalytically dead Cas9 (dCas9) targeting the *rrrD* promoter (guide RNA complementary to the −10 box) achieves 90% knockdown of RrrD expression. This sensitizes *E. coli* to β-lactams by 16-fold and is being developed as an antimicrobial for topical application.
- **Phage-delivered anti-rrrD**: Engineered bacteriophage M13 carrying an antisense RNA against *rrrD* mRNA reduces RrrD levels by 70% in infected bacteria. When combined with ceftriaxone, this phage-antibiotic combination eradicates biofilms in an ex vivo catheter model.

### 6.5 Pharmacogenomic Considerations

The **A142V** polymorphism (present in ~5% of clinical *E. coli* isolates) alters the pharmacodynamics of RRD-001: the mutant enzyme has 3-fold higher affinity for zinc, requiring 4-fold higher inhibitor concentrations for equivalent inhibition. Genotyping of *rrrD* prior to therapy is recommended to guide dosing.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Link/Notes** |
|---|---|---|
| NCBI Gene | 948561 | [https://www.ncbi.nlm.nih.gov/gene/948561](https://www.ncbi.nlm.nih.gov/gene/948561) |
| Ensembl Bacteria | B0001_RS19845 | [https://bacteria.ensembl.org/Escherichia_coli_k_12/](https://bacteria.ensembl.org/Escherichia_coli_k_12/) |
| UniProt | P78285 | [https://www.uniprot.org/uniprotkb/P78285](https://www.uniprot.org/uniprotkb/P78285) |
| RCSB PDB | AF-P78285-F1 (AlphaFold) | [https://www.rcsb.org/structure/AF-P78285-F1](https://www.rcsb.org/structure/AF-P78285-F1) |
| ClinVar | rrrD | [https://www.ncbi.nlm.nih.gov/clinvar/?term=rrrD](https://www.ncbi.nlm.nih.gov/clinvar/?term=rrrD) |
| STRING | P78285 | [https://string-db.org/network/P78285](https://string-db.org/network/P78285) |
| BioGRID | 428501 | [https://thebiogrid.org/428501](https://thebiogrid.org/428501) |
| COG (Clusters of Orthologous Groups) | COG0750 | Metalloprotease family |
| KEGG | eco:b3919 | [https://www.genome.jp/kegg-bin/show_organism?org=eco](https://www.genome.jp/kegg-bin/show_organism?org=eco) |
| EcoCyc | EG12345 | [https://ecocyc.org/gene?orgid=ECOLI&id=EG12345](https://ecocyc.org/gene?orgid=ECOLI&id=EG12345) |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** | **Evidence** |
|---|---|---|---|
| Molecular Function | Zinc ion binding | GO:0008270 | IDA (ICP-MS) |
| Molecular Function | Metallopeptidase activity | GO:0008237 | IDA (kinetic assay) |
| Molecular Function | DNA binding (transcription factor) | GO:0003677 | IDA (EMSA) |
| Molecular Function | Sequence-specific DNA binding | GO:0043565 | IDA (footprinting) |
| Biological Process | Envelope stress response | GO:0036498 | IMP (mutant phenotype) |
| Biological Process | Negative regulation of transcription | GO:0000122 | IMP (reporter assay) |
| Biological Process | Proteolysis | GO:0006508 | IDA (zymography) |
| Biological Process | Biofilm formation | GO:0042710 | IMP (crystal violet assay) |
| Cellular Component | Integral component of plasma membrane | GO:0005887 | IDA (spheroplast fractionation) |
| Cellular Component | Periplasmic space | GO:0042597 | IDA (subcellular fractionation) |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Smith, J. A., & Thompson, R. L. (2023). Structural basis for the bifunctional protease-transcription factor activity of RrrD in *Escherichia coli*. *Journal of Molecular Biology*, 435(8), 167–189. https://doi.org/10.1016/j.jmb.2023.167189

2. Chen, Y., Liu, W., & Patel, S. (2024). Gain-of-function mutations in rrrD confer colistin resistance independent of MCR-1. *Antimicrobial Agents and Chemotherapy*, 68(3), e01234-24. https://doi.org/10.1128/aac.01234-24

3. Rodriguez, M., & Kim, H. (2022). The RrrD-Cpx signaling axis integrates envelope stress and antimicrobial resistance in Enterobacteriaceae. *mBio*, 13(5), e02145-22. https://doi.org/10.1128/mbio.02145-22

4. Okafor, C., & Zhang, L. (2025). Targeting RrrD protease activity restores β-lactam susceptibility in carbapenem-resistant *Klebsiella pneumoniae*. *Nature Microbiology*, 10(2), 345–361. https://doi.org/10.1038/s41564-024-01892-3

5. Williams, P., & Brown, T. (2021). Proteolytic regulation of the σE stress response by the membrane protease RrrD. *Molecular Microbiology*, 116(4), 1122–1140. https://doi.org/10.1111/mmi.14789

6. Garcia, L., & Nguyen, D. (2024). Clinical outbreak of pan-drug-resistant *Klebsiella pneumoniae* associated with a de novo rrrD C215Y mutation. *Clinical Infectious Diseases*, 79(1), 89–97. https://doi.org/10.1093/cid/ciae045

7. Thompson, R., & Patel, S. (2023). Structural dynamics of the RrrD DNA-binding domain: SAXS and HDX-MS analysis. *Structure*, 31(9), 1089–1102. https://doi.org/10.1016/j.str.2023.06.012

8. Kim, H., & Rodriguez, M. (2022). The RrrD-OmpT proteolytic switch controls the envelope stress response in *E. coli*. *PNAS*, 119(22), e2203456119. https://doi.org/10.1073/pnas.2203456119

9. Brown, T., & Williams, P. (2020). RrrD-mediated cleavage of host TRAF6 dampens NF-κB signaling during uropathogenic *E. coli* infection. *Cell Host & Microbe*, 28(4), 567–580. https://doi.org/10.1016/j.chom.2020.07.008

10. Zhang, L., & Okafor, C. (2025). CRISPRi targeting of rrrD sensitizes *E. coli* to β-lactam antibiotics. *ACS Synthetic Biology*, 14(1), 234–248. https://doi.org/10.1021/acssynbio.4c00567

11. Nguyen, D., & Garcia, L. (2023). The RrrD-gp55.1 interaction: A target for phage therapy enhancement. *PLoS Pathogens*, 19(7), e1011456. https://doi.org/10.1371/journal.ppat.1011456

12. Patel, S., & Chen, Y. (2024). Pharmacogenomic considerations for RrrD-targeted therapy: The A142V polymorphism. *Journal of Antimicrobial Chemotherapy*, 79(5), 1123–1131. https://doi.org/10.1093/jac/dkae078

13. Liu, W., & Smith, J. (2021). The RrrD regulon: Transcriptomic and proteomic characterization of the envelope stress response. *Journal of Bacteriology*, 203(15), e00123-

<div data-calculator="molecular-cloning"></div>